Related Experiment Video
Updated: May 29, 2026

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
Iron chelation therapy for transfusional iron overload: a swift evolution
Khaled M Musallam1, Ali T Taher
1Department of Internal Medicine, Hematology-Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon.
Abstract:
Chronic transfusional iron overload leads to significant morbidity and mortality. While deferoxamine (DFO) is an effective iron chelator with over four decades of experience, it requires tedious subcutaneous infusions that reflect negatively on patient compliance. The novel oral iron chelators deferiprone (L1) and deferasirox (DFRA) opened new horizons for the management of transfusional siderosis. A large body of evidence is now available regarding their efficacy and safety in various populations and settings. Nevertheless, experience with both drugs witnessed some drawbacks, and the search for an ideal and cost-effective iron chelator continues.
More Related Videos
Related Concept Videos
The Early Endosome: Endocytosis of Transferrin
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Microbes and Other Elemental Cycles
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Continuous Renal Replacement Therapy

